Literature DB >> 26993887

Prospective, randomized, controlled trial comparing the effectiveness of adjustable compression Velcro wraps versus inelastic multicomponent compression bandages in the initial treatment of leg lymphedema.

Robert J Damstra1, Hugo Partsch2.   

Abstract

BACKGROUND: Inelastic multicomponent compression (ICM) bandages applied by specialized medical staff are the standard of care for compression therapy of lymphedema of the extremities. However, new adjustable compression wraps (ACWs), which can be applied by patients themselves and, up to now, have been mainly recommended for the maintenance treatment phase of lymphedema, may be an important step toward the self-management of the initial treatment phase.
METHODS: This prospective, randomized, controlled comparative study assessed the effectiveness of an ACW in the treatment of leg lymphedema, compared with the traditional treatment with conventional IMC bandages. Included were 30 hospitalized patients admitted due to moderate to severe unilateral lymphedema (stages 2-3) of the leg. The primary outcome measures in both groups were reduction in volume of the affected leg and interface pressure after 2 and 24 hours. Patients were randomized into two groups of 15 patients: group A received ACW and group B received IMC bandages, both applied by experienced staff. After 2 hours, the staff replaced IMC bandages and the patients applied ACW, as previously instructed. Finally, compression was removed after 24 hours. Classic water displacement volumetry was performed before compression and after 2 hours and after 24 hours of compression. The interface pressure was measured immediately after application of compression, 2 hours after compression, before and after compression renewal, and finally, after 24 hours. Patients in the ACW group were allowed to adjust the wrap themselves when they considered it necessary.
RESULTS: The reduction in median volume after 2 hours was 109 mL (interquartile range [IQR], 64-271 mL; -3.1%) in the ACW group and 75 mL (IQR, 41-135; -2.4%) in the IMC group (not significant). After 24 hours, the reduction in median volume was 339 mL (IQR, 231-493 mL; -10.3%) in the ACW group and 190 mL (IQR, 113-296 mL; -5.9%) in the IMC group (P < .05). The interface pressure dropped significantly after 2 and 24 hours in the IMC group (-50% and -6%), but significantly less in the ACW group (-26% and -44%), mainly due to self-readjustment. The median pressures achieved after self-application of ACW (52 mm Hg; IQR, 44-61 mm Hg) were of the same order as those produced by the nurses after the first application of ACW (53 mm Hg; IQR, 39-59 mm Hg), with less variation.
CONCLUSIONS: In patients with moderate to severe lymphedema of the legs, ACW achieved a significantly more pronounced reduction in volume after 24 hours than IMC bandages. Patients were able to apply and adjust the device after being instructed in its use and after an initial 2-hour period of wear. Autonomous handling of ACW seemed to improve the clinical outcome and is a promising step toward self-management involving effective compression.
Copyright © 2013 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID: 26993887     DOI: 10.1016/j.jvsv.2012.05.001

Source DB:  PubMed          Journal:  J Vasc Surg Venous Lymphat Disord


  12 in total

1.  [Compression therapy of chronic leg ulcers : Practical aspects].

Authors:  J Dissemond; K Protz; J Hug; S Reich-Schupke; K Kröger
Journal:  Z Gerontol Geriatr       Date:  2017-02-16       Impact factor: 1.281

2.  [Compression devices for decongestion therapy : A cross-sectional observational survey of handling, pressure, and comfort].

Authors:  K Protz; S Reich-Schupke; K Klose; M Augustin; K Heyer
Journal:  Hautarzt       Date:  2018-03       Impact factor: 0.751

Review 3.  [Medical compression therapy of the extremities with medical compression stockings (MCS), phlebological compression bandages (PCB), and medical adaptive compression systems (MAC) : S2k guideline of the German Phlebology Society (DGP) in cooperation with the following professional associations: DDG, DGA, DGG, GDL, DGL, BVP. German version].

Authors:  E Rabe; E Földi; H Gerlach; M Jünger; G Lulay; A Miller; K Protz; S Reich-Schupke; T Schwarz; M Stücker; E Valesky; F Pannier
Journal:  Hautarzt       Date:  2021-02       Impact factor: 0.751

4.  Compression therapy - cross-sectional observational survey about knowledge and practical treatment of specialised and non-specialised nurses and therapists.

Authors:  Kristina Heyer; Kerstin Protz; Matthias Augustin
Journal:  Int Wound J       Date:  2017-07-25       Impact factor: 3.315

Review 5.  [Evidence of compression therapy with special consideration of medical adaptive compression systems].

Authors:  Joachim Dissemond; Knut Kröger; Markus Stücker
Journal:  Hautarzt       Date:  2020-04       Impact factor: 0.751

Review 6.  [Innovations in medical compression therapy].

Authors:  H Riebe; W Konschake; T Westphal; M Jünger
Journal:  Hautarzt       Date:  2020-01       Impact factor: 0.751

Review 7.  S2k guidelines: diagnosis and treatment of varicose veins.

Authors:  F Pannier; T Noppeney; J Alm; F X Breu; G Bruning; I Flessenkämper; H Gerlach; K Hartmann; B Kahle; H Kluess; E Mendoza; D Mühlberger; A Mumme; H Nüllen; K Rass; S Reich-Schupke; D Stenger; M Stücker; C G Schmedt; T Schwarz; J Tesmann; J Teßarek; S Werth; E Valesky
Journal:  Hautarzt       Date:  2022-04-19       Impact factor: 1.198

Review 8.  [New aspects of compression therapy].

Authors:  Bernhard Partsch; Hugo Partsch
Journal:  Wien Med Wochenschr       Date:  2016-06-03

Review 9.  [Indications and contraindications for modern compression therapy].

Authors:  Joachim Dissemond; Martin Storck; Knut Kröger; Markus Stücker
Journal:  Wien Med Wochenschr       Date:  2017-10-20

10.  Evaluation of Flexible Force Sensors for Pressure Monitoring in Treatment of Chronic Venous Disorders.

Authors:  Suresh Parmar; Iryna Khodasevych; Olga Troynikov
Journal:  Sensors (Basel)       Date:  2017-08-21       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.